Track Q32 Bio Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Q32 Bio Inc. QTTB · Stock Open Q32 Bio Inc. in new tab

8.71 USD
P/E
2.45
EPS
3.56
P/B
0.91
ROE
23.96
Beta
-0.11
Target Price
39.67 USD
Loading chart...
Key Metrics
Earnings dateMarch 9, 2027
P/E2.45
EPS3.56
Book Value9.62
Price to Book0.91
Debt/Equity1.78
% Insiders2.067%
Estimates
Forward P/E-8.54
Forward EPS-1.02
Target Mean Price39.67

DCF valuation

Model fair value for Q32 Bio Inc. (QTTB)
Result
Sign in to run the valuation for QTTB.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus Strong buy · mean target 39.67 USD (low 29.00, high 59.00) · as of 14 Nov 2026
Low 29.00
Mean 39.67
High 59.00
Price 8.71
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Q32 Bio Inc. Logo Q32 Bio Inc. Analysis (QTTB)

Healthcare Official Website Stock

Is Q32 Bio Inc. a good investment? Q32 Bio Inc. (QTTB) is currently trading at 8.71 USD. Market analysts have a consensus price target of 39.67 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 2.45. This relatively low multiple may signal that Q32 Bio Inc. is undervalued compared to historical market norms.

Earnings Schedule: Q32 Bio Inc. is expected to release its next earnings report on March 9, 2027. The market consensus estimate for Forward EPS is -1.02.

Investor FAQ

Does Q32 Bio Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Q32 Bio Inc.?

Q32 Bio Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 9, 2027. The company currently has a trailing EPS of 3.56.

Company Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.

Exchange Ticker
LSE (United Kingdom) 0T6G.L
NASDAQ QTTB
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
March 26, 2024 0.06
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion